2013 American Transplant Congress
Genetic Adaptation of Polyomavirus BK (BKV) to Immunologic and Pharmacologic Selection Pressure
BACKGROUND: Characterizing the genomic plasticity of BKV will further our understanding of viral epidemiology, diagnosis, and clinical outcome, and facilitate development of vaccines and drug…2013 American Transplant Congress
FL/G-CSF/AMD3100 Mobilized Hematopoietic Stem Cells Induce Mixed Chimerism with Nonmyeloablative Conditioning and Transplantation Tolerance without GVHD
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY
Mobilized hematopoietic stem cells (HSC) now serve as a major source for transplantation. Better mobilizing approaches are clinically important. AMD3100, a CXCR4 competitive inhibitor, has…2013 American Transplant Congress
Experience with Linezolid (LZD) for the Treatment of Nocardiosis in Solid Organ Transplant Recipients (SOT)
University of Pittsburgh Medical Center, Pittsburgh; Affiliated Community Medical Centers, Willmar
Objectives: Combination therapy including amikacin is recommended for the treatment of severe Nocardia infections. Use of amikacin in SOT is difficult due to renal dysfunction…2013 American Transplant Congress
Effects of Locoregional Treatment and “Downstaging” on Long-Term Post-Liver Transplant Outcomes for Patients with Hepatocellular Carcinoma
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Research, UNOS, Richmond, VA
IntroductionLocoregional therapy (LRT) has been used to stabilize tumor growth for patients with hepatocellular carcinoma (HCC) waiting for liver transplantation (LT). However, the long-term effects…2013 American Transplant Congress
Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: 5 Years Follow-Up of the ZEUS Trial
ZEUS Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Aim: To follow-up (FU) on renal function (RF), efficacy and safety after conversion to an Everolimus (EVE)/Enteric-Coated Mycophenolate Sodium (EC-MPS) regimen after cyclosporine A (CsA)…2013 American Transplant Congress
Tauroursodeoxycholic Acid Alleviate Ischemia-Reperfusion Injury in Donation after Cardiac Death Liver Transplantation
Background Donation after Cardiac Death (DCD) liver graft can provide possible and practical solutions to the organ shortage crisis, but extended warm ischemia time aggravates…2013 American Transplant Congress
Favorable Post-Transplant Survival for Liver Transplant Recipients with Treated Porto_Pulmonary Hypertension
Background: Portopulmonary hypertension (PPH) was once considered an absolute contraindication for liver transplantation (LT) because of associated high peri- and postoperative mortality rates. With evolution…2013 American Transplant Congress
Causes of Kidney Allograft Loss and Death in the United States, 2000-2010
We sought to describe causes of kidney graft failure (GF) and death with function (DWF) by time posttransplant, and whether causes of immediate GF differed…2013 American Transplant Congress
Geographic Heterogeneity in Use and Outcome of DCD Livers
Background/Aim: Donation after circulatory death (DCD) liver transplants (LTs) are increasingly performed due to organ shortage. Graft survival rates for DCD LTs are inferior to…2013 American Transplant Congress
Outcome on Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 4 Year Data of the APOLLO Trial
APOLLO Study Group, Germany; Novartis Pharma, Nuremberg, Germany
Objective: Assessment of renal function, safety and efficacy of an Everolimus (EVE) regimen after Calcineurin-Inhibitor (CNI) withdrawal in maintenance kidney allograft recipients.Methods: In an open-label,…
- « Previous Page
- 1
- …
- 145
- 146
- 147
- 148
- 149
- …
- 178
- Next Page »